These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 35752614)
1. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. Le Vu S; Bertrand M; Jabagi MJ; Botton J; Drouin J; Baricault B; Weill A; Dray-Spira R; Zureik M Nat Commun; 2022 Jun; 13(1):3633. PubMed ID: 35752614 [TBL] [Abstract][Full Text] [Related]
2. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115 [TBL] [Abstract][Full Text] [Related]
3. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F; PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992 [TBL] [Abstract][Full Text] [Related]
4. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study. Su WJ; Liu YL; Chang CH; Lin YC; Huang WI; Wu LC; Chen SF; Lin YS; Hsieh YL; Yang CA; Lin CH; Chan KA; Lee PI; Chuang JH; Yang CH J Microbiol Immunol Infect; 2023 Jun; 56(3):558-565. PubMed ID: 36804307 [TBL] [Abstract][Full Text] [Related]
5. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537 [TBL] [Abstract][Full Text] [Related]
6. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976 [TBL] [Abstract][Full Text] [Related]
7. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390 [TBL] [Abstract][Full Text] [Related]
9. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines. Naveed Z; Li J; Wilton J; Spencer M; Naus M; Velásquez García HA; Kwong JC; Rose C; Otterstatter M; Janjua NZ; J Am Coll Cardiol; 2022 Nov; 80(20):1900-1908. PubMed ID: 36357091 [TBL] [Abstract][Full Text] [Related]
10. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England. Stowe J; Miller E; Andrews N; Whitaker HJ PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378 [TBL] [Abstract][Full Text] [Related]
11. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States. Hatziantoniou S; Anastassopoulou C; Lazaros G; Vasileiou K; Tsioufis C; Tsakris A Expert Rev Vaccines; 2022 Nov; 21(11):1691-1696. PubMed ID: 35815358 [TBL] [Abstract][Full Text] [Related]
12. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting. Yap J; Tham MY; Poh J; Toh D; Chan CL; Lim TW; Lim SL; Chia YW; Lim YT; Choo J; Ding ZP; Foo LL; Kuo S; Lau YH; Lee A; Yeo KK Ann Acad Med Singap; 2022 Feb; 51(2):96-100. PubMed ID: 35224605 [TBL] [Abstract][Full Text] [Related]
13. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J Nat Med; 2022 Feb; 28(2):410-422. PubMed ID: 34907393 [TBL] [Abstract][Full Text] [Related]
14. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768 [TBL] [Abstract][Full Text] [Related]
15. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322 [TBL] [Abstract][Full Text] [Related]
16. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada. Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096 [TBL] [Abstract][Full Text] [Related]
17. Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: A pragmatic approach. Anastassopoulou C; Hatziantoniou S; Vlachopoulos C; Spanakis N; Tsioufis C; Tsakris A; Lazaros G Int J Cardiol; 2022 Jul; 358():136-139. PubMed ID: 35436559 [TBL] [Abstract][Full Text] [Related]
18. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system. Chen C; Fu F; Ding L; Fang J; Xiao J Front Immunol; 2022; 13():938322. PubMed ID: 36172346 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207 [TBL] [Abstract][Full Text] [Related]
20. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. Block JP; Boehmer TK; Forrest CB; Carton TW; Lee GM; Ajani UA; Christakis DA; Cowell LG; Draper C; Ghildayal N; Harris AM; Kappelman MD; Ko JY; Mayer KH; Nagavedu K; Oster ME; Paranjape A; Puro J; Ritchey MD; Shay DK; Thacker D; Gundlapalli AV MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(14):517-523. PubMed ID: 35389977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]